Skip to content

A Study on Combining Delineation of the Accessory Parotid Gland and Parotid Gland to Improve Xerostomia After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma

A Study on Combining Delineation of the Accessory Parotid Gland and Parotid Gland to Improve Xerostomia After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500097634
Enrollment
Unknown
Registered
2025-02-23
Start date
2025-02-24
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal carcinoma

Interventions

experimental group:According to the side of the accessory parotid gland, outline the accessory parotid gland and the ipsilateral parotid gland as a whole
control group:Only outline the parotid gland, without outlining the accessory parotid gland

Sponsors

Shenshan Medical Centre, Memorial Hospital of Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1: The pathological type is undifferentiated non-keratinizing carcinoma or adenocarcinoma (according to the World Health Organization, WHO's pathological classification). 2: Imaging examinations include nasopharyngeal MRI or CT and whole-body PET/CT to confirm the presence of the accessory parotid gland. 3: Patients will undergo curative dose radiotherapy for nasopharyngeal cancer. 4: Staging is classified as I-IVA (according to the 8th edition of the American Joint Committee on Cancer (AJCC), Table 6), with no evidence of distant metastasis. 5: Age ranges from 18 to 60 years. 6: Patients must be informed of the basic content of the study and provide signed informed consent.

Exclusion criteria

Exclusion criteria: 1: A history of radiotherapy for head and neck tumors, with the exclusion of radiotherapy for other sites. 2: Uncertainty regarding the presence or location of the accessory parotid gland. 3: Women who are pregnant or breastfeeding (for women of childbearing age, pregnancy tests should be considered; effective contraception should be emphasized during treatment). 4: Presence of other serious illnesses that may pose significant risks or affect compliance with the trial. For example: unstable cardiac conditions requiring treatment, renal disease, chronic hepatitis, poorly controlled diabetes (fasting blood glucose > 1.5×ULN), and mental disorders.

Design outcomes

Primary

MeasureTime frame
Incidence of >= Grade II xerostomia;

Countries

China

Contacts

Public Contactxiaoli Yu

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

yxlyxl522@163.com+86 138 2645 2949

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026